IGF2BP2 binds to METTL14 m6A‐modified TGFB2 mRNA and upregulates TGFB2 expression, resulting in enhanced gemcitabine resistance in pancreatic cancer. This evidence concerns the gene IGF2BP2 and familial pancreatic carcinoma.